Rock Springs Expands Biotech
Rock Springs Capital Expands Biotech and Medical Device Holdings, Signaling Strong Sector Conviction
Anonymous
Key Points
1
In Centessa Pharmaceuticals (CNTA), beyond Rock Springs Capital Management LP increasing its stake by 8.6% to 351,828 shares, a broad group of other institutions also expanded their positions, including Eagle Health Investments LP (up 107.8% to 214,291 shares) and Maverick Capital Ltd. (1,854,488 shares), with Rangeley Capital and Weiss Asset Management initiating new positions; overall hedge funds own 82.01% of CNTA.
2
For Cytokinetics (CYTK), Rock Springs Capital Management LP raised its stake by 26.5% to 45,364 shares (worth about $2.99 million), highlighting continued multi-institution accumulation alongside industry giants like Vanguard (12,048,131 shares) and State Street (5,825,295 shares) as top holders. Notable additions include Deep Track Capital's 4.3 million-share stake and Geode Capital Management's 3,056,017 shares.
3
Boston Scientific (BSX) remains a sizable position for Rock Springs Capital, with a 29.1% rise to 515,300 shares, making it the fund’s 16th largest holding and valued at roughly $32.335 million; institutional ownership sits high at 89.07%, and Norges Bank opened a new position in Q4 worth about $2.2 billion.
4
Rock Springs also expanded its exposure to Viking Therapeutics (VKTX), acquiring 96,000 shares for about $3.124 million; other major buyers included Granahan Investment Management, which increased its stake by 96,606 shares to 332,192, and Eversept Partners, along with increases from Manufacturers Life and Quantinno Capital, underscoring broad institutional interest (overall 76.03% of VKTX held by institutions).
Rock Springs Capital Management LP went on a broad buying spree across the healthcare sector, lifting stakes in at least five major companies during the most recent filing period. The moves signal deep, diversified conviction in biopharma and medical devices — from rare disease drugs to cardiac treatments to weight-loss therapies.
The firm's largest reported position shift was in Boston Scientific (BSX), where it boosted holdings by 29.1% to 515,300 shares — a stake now worth roughly $32.3 million. At the same time, Rock Springs added new exposure in names like CVS Health and Dianthus Therapeutics, showing the fund is still actively building its portfolio, according to Watchlist News.
Boston Scientific and Cytokinetics See Big Stake Increases
Rock Springs pushed its Boston Scientific position to 515,300 shares, up 29.1% from the prior period. That makes BSX the fund's 16th largest holding, valued at about $32.3 million. Institutional investors as a whole own 89.07% of Boston Scientific's stock. Norges Bank alone opened a new position in BSX in Q4 worth about $2.2 billion.
For Cytokinetics (CYTK), Rock Springs raised its stake by 26.5% to 45,364 shares, worth about $2.99 million. The fund joins a crowded field of big buyers. Vanguard holds 12,048,131 shares, and State Street owns 5,825,295 shares. Deep Track Capital has built a 4.3 million-share stake. Together, these institutions show broad confidence in CYTK's cardiac drug pipeline.
Viking Therapeutics and Centessa Draw Fresh Institutional Money
Rock Springs acquired 96,000 shares of Viking Therapeutics (VKTX), valued at about $3.12 million. Viking has attracted wide institutional attention. Granahan Investment Management grew its stake by 96,606 shares to 332,192 total. Eversept Partners, Manufacturers Life, and Quantinno Capital also added to their positions. In total, institutions now own 76.03% of VKTX.
In Centessa Pharmaceuticals (CNTA), Rock Springs lifted its stake by 8.6% to 351,828 shares. Other funds moved aggressively too. Eagle Health Investments jumped its position by 107.8% to 214,291 shares. Maverick Capital holds 1,854,488 shares. Rangeley Capital and Weiss Asset Management both opened brand-new positions. Hedge funds now own 82.01% of CNTA — an unusually high concentration.
Alkermes, PTC Therapeutics, and Other Smaller Bets Round Out Strategy
Rock Springs also grew its stake in Alkermes (ALKS) by 32.1%, bringing total holdings to 183,986 shares after buying 44,758 new shares, according to Watchlist News. It raised its PTC Therapeutics (PTCT) position by a striking 161.5% to 161,798 shares. Both moves point to rising conviction in neuro and rare-disease drug makers.
On the other side, Rock Springs trimmed its Celldex Therapeutics (CLDX) position by 42,268 shares, leaving it with 650,270 shares, per Ticker Report. The fund also opened a fresh stake in CVS Health — 40,000 new shares — and initiated a position in Dianthus Therapeutics with 26,757 shares. The mix of buys and trims shows a disciplined, active approach rather than a simple bull run.
A Clear Pattern of High-Conviction Healthcare Accumulation
Across all these moves, one theme stands out: Rock Springs is concentrating capital in companies where institutional ownership is already very high. CNTA is 82% hedge-fund owned. BSX sits at 89% institutional. VKTX is at 76%. These are not ignored corners of the market — they are crowded trades, and Rock Springs is leaning in.
The fund spans cardiac drugs, weight-loss therapies, rare diseases, and medical devices — a wide net. But the consistent thread is size and scale: most of Rock Springs's targets already have deep institutional backing. That suggests the firm is betting on mature, well-researched opportunities rather than speculative early-stage plays.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
10
Reach
21
Topics
A
AnonymousAuthor
